Clinical Advances in
There is strong evidence supporting the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in improving thromboembolic outcomes across a range of populations. Despite guideline recommendations for NOACs for the treatment of atrial fibrillation (AF) and venous thromboembolism (VTE), they are still widely underutilized or inappropriately applied. The Clinical Advances in Evolving Anticoagulation in AF and VTE is designed to update healthcare professionals on effective anticoagulation therapy in patients at risk for stroke or VTE.
Supported by an independent educational grant from
Daiichi-Sankyo Europe GmbH
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention.
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Professor of Cardiology
Director, University Cardiology Division
Pisa University Hospital
University of Pisa
Pisa, Italy
Senior Professor of Clinical Neurosciences
Department of Neurology and Stroke Center
University Hospital Essen
University Duisburg
Essen, Germany
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States
Professor of Medicine
Department of Cardiology and Intensive Care Medicine
St. Vincenz Hospital
Paderborn, Germany
Director
General Institute for Clinical Research
Osaka National Hospital
Osaka, Japan
Regents Professor, Medicine and Epidemiology
Dean, College of Public Health
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Professor of Medicine and Biochemistry
Hamilton, Ontario, Canada